NCT06802081View on ClinicalTrials.gov

TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 8, 2025

Primary Completion Date

June 1, 2026

Study Completion Date

December 31, 2026

Conditions
Atrial FibrillationObesity
Interventions
DRUG

Tirzepatide

Weekly subcutaneous injections starting with dose 2.5mg, then increase dose by 2.5mg at week 4 (5mg), week 8 (7.5mg) and at week12 (10mg) as tolerated.

DRUG

Placebo

Weekly subcutaneous injections starting with dose 2.5mg, then increase dose by 2.5mg at week 4 (5mg), week 8 (7.5mg) and at week 12 (10mg).

Trial Locations (1)

44195

RECRUITING

Cleveland Clinic, Cleveland

All Listed Sponsors
lead

The Cleveland Clinic

OTHER